Bandhan AMC Limited has announced the declaration of dividend for its Large & Mid Cap Fund under the Income Distribution cum Capital Withdrawal Option (IDCW), marking a positive development for investors. The Board of Directors of Bandhan Mutual Fund Trustee Limited has approved this dividend distribution with specific terms and conditions.

Dividend Declaration Details

The dividend has been approved with the record date set as Tuesday, March 10, 2026. The declaration is subject to availability of distributable surplus and follows regulatory compliance requirements. The fund, formerly known as Bandhan Core Equity Fund, offers different dividend rates for Regular and Direct plans.

The NAV figures are as on March 04, 2026, with a face value of ₹10 per unit for both plans.

Eligibility and Important Conditions

All investors whose names appear in the register of unit holders of the scheme/plan/option as on the close of the record date will be eligible to receive the dividend. The company has specified that TDS and other statutory levies will be applicable on the amount received by investors.

Considering the volatile nature of markets, the Trustee reserves the right to restrict the quantum of dividend up to the per unit distributable surplus available on the record date in case of market fall. If the record date falls on a non-business day, the immediately following business day shall be deemed to be the record date.

Post-Dividend Impact

Pursuant to the payment of dividend, the NAV of the scheme/plan/option will fall to the extent of payout and statutory levy, if any. This is a standard practice in mutual fund dividend distributions where the NAV adjusts to reflect the dividend payment.

The notice was dated March 05, 2026, and includes the standard disclaimer that mutual fund investments are subject to market risks, advising investors to read all scheme-related documents carefully before investing.

Dr lalchandani labs has received a disclosure from Anuraag Gambhir regarding substantial acquisition of shares under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosure, dated March 05, 2026, reveals a significant increase in Gambhir's shareholding through a rights issue allotment.

Acquisition Details

Anuraag Gambhir acquired 13,00,000 equity shares through rights issue allotment completed on March 02, 2026. This acquisition represents a substantial 15.05% of the company's total voting capital, marking a significant investment in the pharmaceutical company.

Shareholding Pattern Changes

The acquisition resulted in a dramatic change in Gambhir's shareholding position. Prior to this transaction, he held a minimal stake of just 02 shares with negligible percentage holding.

Company Capital Structure Impact

The rights issue significantly expanded Dr. Lalchandani Labs Limited's equity base. The company's equity share capital increased substantially following the completion of the rights issue.

Regulatory Compliance

The disclosure was made in compliance with Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Gambhir confirmed that he does not belong to the promoter or promoter group category. The company's shares are listed on BSE Limited, and the disclosure has been filed with both the stock exchange and the company's board of directors.

This substantial acquisition represents one of the significant shareholding changes in Dr. Lalchandani Labs Limited, with Gambhir emerging as a notable shareholder through the rights issue participation.